BioDMET: A physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 39, Issue 1, 2012, Pages 37-54

  Graf, John F ^a   Scholz, Bernhard J ^a   Zavodszky, Maria I ^a  

^a GE GLOBAL RESEARCH   (United States)

Author keywords

Biodistribution; Imaging; Mechanistic model; PBPK modeling; Pharmacokinetics; Whole body model

Indexed keywords

ACCURACY; ALGORITHM; ARTICLE; BIOTRANSFORMATION; CALCULATION; CLEARANCE; COMPARTMENT MODEL; COMPUTER INTERFACE; COMPUTER MODEL; COMPUTER SIMULATION; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; MATHEMATICAL COMPUTING; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; SENSITIVITY AND SPECIFICITY; SIMULATOR; VALIDATION PROCESS;

ALGORITHMS; ANIMAL STRUCTURES; ANIMALS; BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; BODY FLUIDS; CEFOTAXIME; CEPHALOSPORINS; COMPUTER SIMULATION; CONTRAST MEDIA; DATABASES, FACTUAL; EUKARYOTIC CELLS; GUINEA PIGS; HAPLORHINI; HUMANS; INTERNET; IOHEXOL; MICE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RATS; REPRODUCIBILITY OF RESULTS; SOFTWARE; TISSUE DISTRIBUTION; USER-COMPUTER INTERFACE;

EID: 84861482858     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-011-9229-x     Document Type: Article

References (61)

1. Leahy DE (2004) Drug discovery information integration: virtual humans for pharmacokinetics. Biosilico 2:78-84 (Pubitemid 40136864)
2. Lin J, Sahakian DC, de Morais SM, Xu JJ, Polzer RJ, Winter SM (2003) The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr Top Med Chem 3:1125-1154
3. van de Waterbeemd H, Gifford E (2003) ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2:192-204 (Pubitemid 37361664)
4. Peters SA, Ungell AL, Dolgos H (2009) Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization. Curr Opin Drug Discov Devel 12:509-518
5. EPA. US (2006) Approaches for the application of physiologically based pharmacokinetic (PBPK) models and supporting data in risk assessment (Final report). EPA/600/R-05/043F
6. EPA. US (2006) Use of physiologically based pharmacokinetic (PBPK) models to quantify the impact of human age and inter-individual differences in physiology and biochemistry pertinent to risk (Final report). EPA/600/R-06/014A
7. Charnick SB, Kawai R, Nedelman JR, Lemaire M, Niederberger W, Sato H (1995) Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development. J Pharmacokinet Biopharm 23:217-229 (Pubitemid 26076916)
8. Leahy DE (2003) Progress in simulation modelling for pharmacokinetics. Curr Top Med Chem 3:1257-1268
9. Edginton AN, Theil FP, Schmitt W, Willmann S (2008) Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 4:1143-1152
10. Parrott N, Jones H, Paquereau N, Lave T (2005) Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. Basic Clin Pharmacol Toxicol 96:193-199 (Pubitemid 40387995)
11. Sinskey AJ, Finkelstein SN, Cooper SM (2004) Medical imaging in drug discovery, Part I. PharmaGenomics. March/April:20-25, Advanstar Communications, Edison, NJ
12. Finkelstein SN, Sinskey AJ, Cooper SM (2004) Medical imaging in drug discovery, Part II. PharmaGenomics. May:20-24, Advanstar Communications, Edison, NJ
13. Grass GM, Sinko PJ (2002) Physiologically-based pharmacokinetic simulation modelling. Adv Drug Deliv Rev 54:433-451 (Pubitemid 34260962)
14. Jones HM, Gardner IB, Watson KJ (2009) Modelling and PBPK simulation in drug discovery. AAPS J 11:155-166
15. Lave T, Parrott N, Grimm HP, Fleury A, Reddy M (2007) Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 37: 1295-1310 (Pubitemid 350035528)
16. Nestorov I (2007) Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 3:235-249
17. Rowland M, Balant L, Peck C (2004) Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). AAPS PharmSci 6:E6
18. Schmitt W, Willmann S (2004) Physiology-based pharmacokinetic modeling: ready to be used. Drug Discov Today Technol 1:449-456 (Pubitemid 40186349)
19. Thygesen P, Macheras P, Van Peer A (2009) Physiologicallybased PK/PD modelling of therapeutic macromolecules. Pharm Res 26:2543-2550
20. Parrott N, Paquereau N, Coassolo P, Lave T (2005) An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J Pharm Sci 94:2327-2343 (Pubitemid 41670503)
21. Marx V (2005) Molecular imaging: companies set out to sharpen the in vivo perspective with new machines and novel contrast agents. Chem Eng News 83:25-34
22. Massoud TF, Gambhir SS (2003) Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17:545-580 (Pubitemid 36307540)
23. Barboriak DP, MacFall JR, Viglianti BL, Dewhirst Dvm MW (2008) Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging. J Magn Reson Imaging 27:1388-1398 (Pubitemid 351770694)
24. Mescam M, Kretowski M, Bezy-Wendling J (2010) Multiscale model of liver DCE-MRI towards a better understanding of tumor complexity. IEEE Trans Med Imaging 29:699-707
25. Mescam M, Eliat PA, Fauvel C, Certaines JD, Bezy-Wendling J (2007) A physiologically based pharmacokinetic model of vascular- extravascular exchanges during liver carcinogenesis: application to MRI contrast agents. Contrast Media Mol Imaging 2:215-228 (Pubitemid 351166058)
26. Kretowski M, Bezy-Wendling J, Coupe P (2007) Simulation of biphasic CT findings in hepatic cellular carcinoma by a two-level physiological model. IEEE Trans Biomed Eng 54:538-542 (Pubitemid 46371236)
27. GastroPlus. http://www.simulations-plus.com/Products.aspx?grpID= 3&cID=16&pID=11 (accessed 2009)
28. SimCyp. http://www.simcyp.com/ProductServices/Simulator/ (accessed 2009)
29. Willmann S, Lippert J, Sevestre M, Solodenko J, Fois F, Schmitt W (2003) PK-Sim®: a physiologically based pharmacokinetic "whole-body" model. Biosilico 1:121-124 (Pubitemid 40416764)
30. PK-Sim. http://www.systems-biology.com/products/pk-sim.html (accessed 2009)
31. MEGen: the PBPK database & model equation generator. http:// xnet.hsl.gov.uk/megen/ (accessed 2009)
32. JSim. http://www.physiome.org/jsim/ (accessed 2009)
33. Levitt DG (2002) PKQuest: a general physiologically based pharmacokinetic model. introduction and application to propranolol. BMC Clin Pharmacol 2:5
34. Levitt DG (2009) PKQuest-Java: free, interactive physiologically based pharmacokinetic software package and tutorial. BMC Res Notes 2:158
35. SAAM II: simulation, analysis and modeling software for kinetic analysis. http://depts.washington.edu/saam2/ (accessed 2011)
36. acslX Software for Modeling and Simulation. http://www.acslsim.com/ (accessed 2010)
37. Leahy DE (2006) Integrating in vitro ADMET data through generic physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 2:619-628 (Pubitemid 46118330)
38. Brightman FA, Leahy DE, Searle GE, Thomas S (2006) Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in rat plasma. Drug Metab Dispos 34:84-93 (Pubitemid 43042649)
39. Brightman FA, Leahy DE, Searle GE, Thomas S (2006) Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. Drug Metab Dispos 34:94-101 (Pubitemid 43042650)
40. Cloe® PK. https://www.cloegateway.com/ (accessed 2009)
41. Blancato JN, Power FW, Brown RN, Dary CC (2006) Exposure related rose estimating model (ERDEM) a physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) model for assessing human exposure and risk. EPA/600/R-06/061
42. CEMC - PBPK Model. http://www.trentu.ca/academic/aminss/envmodel/models/ PBPK100.html (accessed 2010)
43. Brissova M, Fowler MJ, Nicholson WE, Chu A, Hirshberg B, Harlan DM, Powers AC (2005) Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J Histochem Cytochem 53:1087-1097 (Pubitemid 41262977)
44. Rippe B, Haraldsson B (1994) Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev 74:163-219 (Pubitemid 24045677)
45. Guyton AC, Hall JE (2005) Medical physiology. Saunders, Philadelphia
46. Lazzara MJ, Deen WM (2007) Model of albumin reabsorption in the proximal tubule. Am J Physiol Renal Physiol 292:F430-F439 (Pubitemid 46105281)
47. Birn H, Christensen EI (2006) Renal albumin absorption in physiology and pathology. Kidney Int 69:440-449 (Pubitemid 43164434)
48. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479
49. Simionescu M, Simionescu N, Palade GE (1974) Morphometric data on the endothelium of blood capillaries. J Cell Biol 60:128-152
50. Takakura Y, Mahato RI, Hashida M (1998) Extravasation of macromolecules. Adv Drug Deliv Rev 34:93-108 (Pubitemid 28464480)
51. Lum H, Malik AB (1994) Regulation of vascular endothelial barrier function. Am J Physiol 267:L223-L241
52. Gaumet M, Vargas A, Gurny R, Delie F (2008) Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm 69:1-9 (Pubitemid 351467152)
53. Ballet F (1990) Hepatic circulation: potential for therapeutic intervention. Pharmacol Ther 47:281-328
54. Henderson JR, Moss MC (1985) A morphometric study of the endocrine and exocrine capillaries of the pancreas. Q J Exp Physiol 70:347-356 (Pubitemid 15070871)
55. Fujikawa M, Nakao K, Shimizu R, Akamatsu M (2007) QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg Med Chem 15:3756-3767 (Pubitemid 46635142)
56. Chou C, McLachlan AJ, Rowland M (1995) Membrane permeability and lipophilicity in the isolated perfused rat liver: 5-ethyl barbituric acid and other compounds. J Pharmacol Exp Ther 275:933-940 (Pubitemid 26027052)
57. Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, Inc., New York
58. Muller M, Haag O, Burgdorff T, Georgopoulos A, Weninger W, Jansen B, Stanek G, Pehamberger H, Agneter E, Eichler HG (1996) Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. Antimicrob Agents Chemother 40:2703-2709 (Pubitemid 26404329)
59. Gaspari F, Perico N, Ruggenenti P, Mosconi L, Amuchastegui CS, Guerini E, Daina E, Remuzzi G (1995) Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 6:257-263
60. Graf JF, Sarachan BD, Spliker ME (2008) Method and apparatus for assessing feasibility of probes and biomarkers. US Patent Application US20100106423A1, Published 29 Apr 2010; Filed 28 Oct 2008
61. Zavodszky MI, Graf JF, Tan Hehir CA (2011) Feasibility of imaging myelin lesions in multiple sclerosis. Int J Biomed Imaging 2011:953806